Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.74 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.74 |
| ▸ | OSBP | P22059 | 1/20 | 0.74 |
| ▸ | RORC | P51449 | 1/20 | 0.74 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.74 |
| ▸ | GRIN1 | Q05586 | 15/20 | 0.68 |
| ▸ | GRIN2B | Q13224 | 15/20 | 0.68 |
| ▸ | GRIN2A | Q12879 | 13/20 | 0.67 |
| ▸ | POLA1 | P09884 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103515 | 1.00 | USP2 (0.74) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL932623 | 1.00 | USP2 (0.74) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL4961477 | 0.92 | GRIN1 (0.80) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL5935410 | 0.92 | GRIN1 (0.80) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL21822074 | 0.91 | OSBP (0.75) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL10887781 | 0.90 | USP2 (0.71) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL8930167 | 0.90 | USP2 (0.71) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL18529717 | 0.90 | USP2 (0.71) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL720338 | 0.90 | USP2 (0.71) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL10943687 | 0.90 | USP2 (0.71) | USP2CYP46A1LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117587045-B | Veratric cholesterol 22 (R) -hydroxylase VnCYP B27 gene and application thereof | 云南农业大学 | 2024-04-16 | — | — | CN | claimed |
| CN-117587045-A | Veratric cholesterol 22 (R) -hydroxylase VnCYP90B27 gene and application thereof | 云南农业大学 | 2024-02-23 | — | — | CN | claimed |
| CN-116322710-A | Pharmaceutical composition comprising gamma-cyclodextrin polymer and use thereof | 株式会社雷纳图斯 | 2023-06-23 | — | — | CN | claimed |
| WO-2019176857-A1 | PROMOTER FOR INDUCING DIFFERENTIATION OF INSULIN-PRODUCING CELLS | 味の素株式会社 | 2019-09-19 | — | — | WO | claimed |
| WO-2006007528-A9 | LXR/RXR-RELATED METHODS AND COMPOSITIONS | UNIV COLUMBIA (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2006007528-A2 | LXR/RXR-RELATED METHODS AND COMPOSITIONS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-01-19 | — | — | WO | claimed |
| JP-2002506817-A | — | — | 2002-03-05 | — | — | JP | claimed |
| EP-1063989-A1 | PREVENTION AND TREATMENT OF ADHESIONS | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2001-01-03 | — | — | EP | claimed |
| WO-1999047136-A1 | PREVENTION AND TREATMENT OF ADHESIONS | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 1999-09-23 | — | — | WO | claimed |
| EP-4638461-A1 | DUAL LIPID STRUCTURES | Turn Biotechnologies, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4638465-A1 | IONIZABLE LIPIDS WITH DEGRADABLE HEAD | Turn Biotechnologies, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250305010-A1 | LIPID COMPOSITIONS AND METHODS OF PRODUCING SAME | WILK TECHNOLOGIES INTERNATIONAL LTD. (IL) | 2025-10-02 | — | — | US | disclosed |
| US-12171909-B2 | Implants having a drug load of an oxysterol and methods of use | WARSAW ORTHOPEDIC, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2024138034-A1 | IONIZABLE LIPIDS WITH DEGRADABLE HEAD | TURN BIOTECHNOLOGIES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20030153541-A1 | Novel anticholesterol compositions and method for using same | ANAGEN THERAPEUTICS, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2001083506-A1 | HUMAN ABC1 PROMOTER AND ASSAYS BASED THEREON | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2001-11-08 | — | — | WO | disclosed |
| EP-1063989-A1 | PREVENTION AND TREATMENT OF ADHESIONS | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2001-01-03 | — | — | EP | disclosed |
| EP-1063989-A1 | PREVENTION AND TREATMENT OF ADHESIONS | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047136-A1 | PREVENTION AND TREATMENT OF ADHESIONS | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999047136-A1 | PREVENTION AND TREATMENT OF ADHESIONS | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12171909-B2 | Implants having a drug load of an oxysterol and methods of use | SOST, CYP17A1, HSD17B7 | USP2 900/4885CYP46A1 8/4885LMNA 1681/4885 |
| US-20030153541-A1 | Novel anticholesterol compositions and method for using same | CYP46A1, NR1H4, NR1H3 | USP2 3773/4885CYP46A1 1/4885LMNA 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.